Similarly, DC-based high hydrostatic pressure (HHP) lung cancer vaccine decreased the number of CD4+CD25+Foxp3+ Tregs and Increased IFN-γ-producing tumor antigen-specific CD4+ and CD8+ T cells from non-small cell lung cancer (NSCLC) patients. This evidence concerns the gene CD4 and lung carcinoma.